Jiangsu Hengrui Medicine Co. Ltd.
No. 145 East Renmin Road
Lianyungang
Jiangsu
China
Tel: 800-828-3900
Website: http://www.hrs.com.cn/
Email: hrs@hrs.com.cn
28 articles about Jiangsu Hengrui Medicine Co. Ltd.
-
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
10/30/2023
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.
-
Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies
10/30/2023
Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.
-
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) launches Luzsana Biotechnology™ (Luzsana)
5/18/2022
Luzsana to co-develop medicines with parent company Hengrui Pharma and commercialize in North America, Europe and Japan.
-
Hengrui Pharma is seeking to make medicines more available and affordable worldwide with the launch of Luzsana that opens up access to treatment for hundreds of illnesses.
-
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
-
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
11/21/2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region.
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions
6/17/2019
VT-1161 is a potent antifungal therapy with the potential to treat a range of fungal infections, including those resistant to currently approved treatment options
-
LSK BioPharma and Jiangsu Hengrui Medicine Announce FDA Clearance to Initiate a Phase 3 Clinical Trial in Advanced Hepatocellular Carcinoma (HCC)
4/9/2019
LSK BioPharma and Jiangsu Hengrui Medicine, Co., Ltd. announced that the Companies have received FDA clearance to initiate a clinical trial in the United States
-
LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)
10/22/2018
LSK BioPharma and Jiangsu Hengrui Medicine, Co., Ltd. today announced that the companies have entered into a global clinical collaboration in patients with advanced hepatocellular carcinoma
-
TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies
1/8/2018
In addition to TG-1701, the global license agreement covers TG-1702 (SHR-1266), another BTK inhibitor in pre-clinical development.
-
Jiangsu Hengrui Medicine and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302
1/5/2018
Jiangsu Hengrui Medicine and Arcutis today announced an exclusive option and license agreement for the development and commercialization of topical applications of Hengrui’s investigational drug, SHR0302.
-
Jiangsu Hengrui Medicine Co. Ltd. Signs MOU For China Rights To Oncolytic Virus Drug
5/24/2016
-
Jiangsu Hengrui Medicine Co. Ltd. Enters Into Agreement With The University of Texas MD Anderson Cancer Center To Advance Immunotherapy And Precision Medicine For Cancer Treatment
5/3/2016
-
Jiangsu Hengrui Medicine Co. Ltd. Announce Collaboration With Albert Einstein College of Medicine To Advance Cancer Research And Drug Discovery
4/26/2016
-
Jiangsu Hengrui Medicine Co. Ltd. Uses Partnerships To Advance Novel Drug Programs
2/10/2016
-
Jiangsu Hengrui Medicine Co. Ltd. To Build $240 Million Biopharma Plant In Jiangsu
9/14/2015
-
Week In Review: Jiangsu Hengrui Medicine Co. Ltd. Out-licenses Cancer Drug In $795 Million Deal
9/8/2015
-
Incyte, Jiangsu Hengrui Medicine Co. Ltd. Forge $795M+ Anti-PD-1 Monoclonal Antibody Pact
9/2/2015
-
Tesaro, Inc. And Jiangsu Hengrui Medicine Co. Ltd. Announce Rolapitant License Agreement For China
7/30/2015